Development and characterization of liposomal formulation of bortezomib

Bortezomib is a proteasome inhibitor used for the treatment of multiple myeloma. The poor pharmacokinetic profile and off-target adverse effects provide a strong incentive to develop drug delivery systems for bortezomib. In the past, liposomal encapsulation has been proven to improve the therapeutic...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Int J Pharm X
Autors principals: Deshantri, Anil K., Metselaar, Josbert M., Zagkou, Stavroula, Storm, Gert, Mandhane, Sanjay N., Fens, Marcel H.A.M., Schiffelers, Raymond M.
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6733293/
https://ncbi.nlm.nih.gov/pubmed/31517276
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ijpx.2019.100011
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars